Page 144 - Haematologica May 2022

R.J. Lin et al.
in the elderly. Curr Hematol Malig Rep.
2019;14(4):228-238.
6. Morrison VA, Hamlin P, Soubeyran P, et al.
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Ann Oncol. 2015;26(6):1058-1068.
7. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626-633.
8. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B- cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2):105-116.
9. Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced- dose CHOP for diffuse large B-cell lym- phomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4(1):e46-e55.
10. Madsen ML, Due H, Ejskjaer N, Jensen P, Madsen J, Dybkaer K. Aspects of vin- cristine-induced neuropathy in hematolog- ic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019; 84(3):471-485.
11. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326-2347.
12. DuMontier C, Loh KP, Bain PA, et al. Defining undertreatment and overtreat- ment in older adults with cancer: a scoping literature review. J Clin Oncol. 2020; 38(22):2558-2569.
13. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicen- ter study. J Clin Oncol. 2011;29(25):3457- 3465.
14. Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366- 2371.
15. Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehen- sive geriatric assessment for elderly patients with diffuse large B-cell lym- phoma. Blood. 2017;130(20):2180-2185.
16. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
17. Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path for- ward. Cell. 2019;179(4):813-827.
18. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013; 123(3):966-972.
19. Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019; 19(8):439-453.
20. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140(6):734-739.
21. Guigoz Y, Vellas B. The Mini Nutritional Assessment (MNA) for grading the nutri- tional state of elderly patients: presentation of the MNA, history and validation. Nestle Nutr Workshop Ser Clin Perform Programme. 1999;1:3-11; discussion 11-12.
22.Lakshmaiah KC, Asati V, Babu KG, et al. Role of prephase treatment prior to defini- tive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018;100(6):644-648.
23. Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in dif- fuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study. Eur J Cancer. 2018;99:86-96.
24. Klepin HD. Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. Blood. 2019; 134(23):2005-2012.
25. Abel GA, Klepin HD. Frailty and the man- agement of hematologic malignancies. Blood. 2018;131(5):515-524.
26.Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical out- comes in older patients with hematologic malignancies. Blood. 2019;134(4):374-382.
27.Hshieh TT, Jung WF, Grande LJ, et al. Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers. JAMA Oncol. 2018;4(5):686-693.
28. Saad M, Loh KP, Tooze JA, et al. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020; 136(23):2715-2719.
29. Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment deci- sions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma. 2015;56(4):921-926.
30. Merli F, Luminari S, Rossi G, et al. Outcome of frail elderly patients with diffuse large B- cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2014; 55(1):38-43.
31.
32.
Bai JF, Han HX, Feng R, et al. Comprehensive geriatric assessment (CGA): a simple tool for guiding the treat- ment of older adults with diffuse large B-cell lymphoma in China. Oncologist. 2020;25(8):e1202-e1208.
Olivieri A, Gini G, Bocci C, et al. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist. 2012;17(5):663-672.
33.Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assess- ment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17(6):838-846.
34. Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lym- phoma: the Prospective Elderly Project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021;39(11):1214-1222.
35. Bowcock SJ, Fontana V, Patrick HE. Very poor performance status elderly patients with aggressive B cell lymphomas can ben- efit from intensive chemotherapy. Br J Haematol. 2012;157(3):391-393.
36. Voog E, Bienvenu J, Warzocha K, et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand- receptor system. J Clin Oncol. 2000; 18(2):325-331.
37.Dlouhy I, Filella X, Rovira J, et al. High serum levels of soluble interleukin-2 recep- tor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lym- phoma. Leuk Res. 2017;59:20-25.
38. Zhong H, Chen J, Cheng S, et al. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma. EBioMedicine. 2019;41:167-174.
39. Loh KP, Tooze JA, Nicklas BJ, et al. Inflammatory biomarkers, geriatric assess- ment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020; 11(3):410-416.
40. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554- 563.
41. Chen Y, Liu S, Leng SX. Chronic low-grade inflammatory phenotype (CLIP) and senes- cent immune dysregulation. Clin Ther. 2019;41(3):400-409.
42. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lym- phoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19(13):3659- 3670.
1152
haematologica | 2022; 107(5)